NFE2L2 and Alzheimer disease: In our study, we also observed that eriodictyol inhibited the pathological features of AD by activating the Nrf2/HO-1 signaling pathway, including promoting the phosphorylation (Ser40) and nuclear translocation of Nrf2, thereby up-regulating the expression of HO-1.